COMP <GO>
HLF vs LLY // ENTERPRISE SCALE & MARKET CAP
Herbalife Ltd. (NYSE) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: HLF 4
— LLY 9
▲ ENTERPRISE SCALE & MARKET CAP LEADER: LLY
LAST: $12.93 (-3.36%) • MKT CAP: $1.36B
market-cap
$1.36B
LAST: $1,373.70 (+6.63%) • MKT CAP: $1.29T
market-cap
$1.29T
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (HLF VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | HLF | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 77.90% | 83.64% | -5.74 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 34.40% | 32.36% | +2.04 | HLF | /roic <GO> |
| EV/EBITDA & P/E Valuation | 5.4x | 36.4x | -31.02 | HLF | /valuation <GO> |
| Free Cash Flow Yield | 18.66% | 2.30% | +16.36 | HLF | /fcf-yield <GO> |
| Operating Margin | 9.50% | 40.21% | -30.71 | LLY | /operating-margins <GO> |
| Net Profit Margin | 4.50% | 31.90% | -27.40 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 0.90% | 45.51% | -44.61 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.39 | 9.29 | -6.90 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 9/9 | -3.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.77% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 47.5 | 66.6 | -19.08 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.51 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 5.5x | 26.3x | -20.75 | HLF | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $1.36B | $1.29T | -$1.29T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | HLF REV | LLY REV | HLF GROSS % | LLY GROSS % | HLF FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $5.04B | $65.18B | 77.9% | 83.0% | $252.9M | $16.81B |
| FY 2024 | $4.99B | $45.04B | 77.9% | 81.3% | $163.4M | $8.82B |
| FY 2023 | $5.06B | $34.12B | — | 79.3% | $357.5M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
HLF // BETA —
LLY // BETA 0.51